SIRT2-IN-9

Research use only, not for human use.

SIRT2-IN-9 is a selective SRIT2 inhibitor with an IC50 value of 1.3 μM.SIRT2-IN-9 inhibits the proliferation of MCF-7 breast cancer cells.SIRT2-IN-9 can be used for cancer research.

SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer.

SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC50 value of 1.3 μM, and inhibits SRIT1 and SRIT3 with IC50s ＞300 μM.SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells.SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein.Cell Proliferation Assay Cell Line:MCF-7 breast cancer cell line Concentration:0-50 μM Incubation Time:72 hours Result:Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells.Western Blot Analysis Cell Line:MCF-7 breast cancer cell line Concentration:6.25, 12.5, 25 and 50 μM Incubation Time:6 hours Result:Dose-dependently increased acetylation of α-tubulin protein.

——

——

Chromatin/Epigenetic

Sirtuin

Sirtuin

——

——

522650-91-5

438.57

C21H22N6OS2

>98% (HPLC)

In Vitro:?DMSO : 4.46 mg/mL (10.17 mM; Ultrasonic (<70°C)

CCCn1c2ccccc2c2nnc(SCC(=O)Nc3nc4CCCCc4s3)nc12

——

(-20℃)

With Ice Pack

≥ 2 years